Compare Mesoblast Limited (MESO) vs Waste Management, Inc. (WM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Waste Management, Inc. — how do they compare? Mesoblast Limited trades at $14.21 (market cap $1.75B), while Waste Management, Inc. trades at $208.98 (market cap $83.98B). The key difference: Waste Management, Inc. is far larger — about 48× Mesoblast Limited's market cap, and Waste Management, Inc. pays a 1.8% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals — on Pluang, investors hold Mesoblast Limited for 14 Days and Waste Management, Inc. for 130 Days on average.
| MESO | WM | |
|---|---|---|
Market Cap | $1.75B | $83.98B |
Volume | 239,027 | 2,182,180 |
Sector | Health | Industrials |
52-Week High | $20.96 | $246.51 |
52-Week Low | $13.19 | $196.77 |
Typical Hold Time | 14 Days | 130 Days |
Enterprise Value | $1.83B | $106.78B |
Dividend Yield | — | 1.8% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $13.94, up 2.42% with bearish technical signals from moving averages. The company reported substantial revenue growth to $120 million in 2026 but remains unprofitable with a -47.82% net margin. Recent FDA approval for Ryoncil potency assay and completion of Phase 3 back pain trial represent significant operational milestones. Cash position remains strong at $161.16 million, though debt levels require monitoring.
While MESO shows promising revenue growth and pipeline progress, persistent losses and negative ROE present fundamental challenges. Analyst consensus leans bullish with 45% buy ratings, but technical indicators suggest near-term caution. The stock offers speculative growth potential contingent on successful commercialization and path to profitability.
WM trades at $208.94, up 0.51% today, with a bearish technical signal but strong fundamentals including 11.12% net income margin and 29.83% ROE. Recent earnings show beats in Q1 and Q2 2026, while Q4 2025 missed estimates. Revenue grew to $25.20B in 2025, and cash flow from operations remains robust at $6.04B. Analyst sentiment is positive with 54% buy ratings and no sell recommendations.
The outlook is supported by steady revenue growth and high profitability, but risks include elevated debt levels and competitive pressures. The stock's valuation at a P/E of 29.72 may limit near-term upside, though institutional backing and dividend payments provide stability. Investors should weigh solid cash generation against debt concerns and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Waste Management, Inc.
Waste Management ranks as the largest integrated provider of traditional solid waste services in the United States, operating approximately 260 active landfills and about 340 transfer stations. The company serves residential, commercial, and industrial end markets and is also a leading recycler in North America.
Read more on WM →
